83416-40-4

Usage

Uses

Used in Medical Research:
1-α-D-Arabinofuranosyl-2-nitro-1H-imidazole is used as a synthon for the development of potential markers of tissue hypoxia. 1-α-D-Arabinofuranosyl-2-nitro-1H-iMidazole plays a crucial role in identifying areas of low oxygen levels within tissues, which is essential for understanding various physiological and pathological processes. By serving as a precursor for the synthesis of hypoxia markers, 1-α-D-Arabinofuranosyl-2-nitro-1H-iMidazole aids researchers in the development of diagnostic tools and therapeutic strategies targeting hypoxic conditions.
Used in Pharmaceutical Industry:
1-α-D-Arabinofuranosyl-2-nitro-1H-imidazole is used as a key intermediate in the synthesis of pharmaceutical compounds targeting hypoxia-related diseases. 1-α-D-Arabinofuranosyl-2-nitro-1H-iMidazole's unique structure allows for the creation of novel drug candidates that can specifically target hypoxic cells, potentially leading to more effective treatments for conditions such as cancer, where hypoxia is often associated with aggressive tumor growth and resistance to therapy.
Used in Diagnostic Imaging:
1-α-D-Arabinofuranosyl-2-nitro-1H-imidazole is used as a building block for the development of contrast agents for diagnostic imaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET). These contrast agents can help visualize areas of tissue hypoxia, providing valuable information for the diagnosis and monitoring of diseases associated with hypoxic conditions.

Upstream product

• 193150-87-7 1-(2-benzoyl-α-D-arabinofuranosyl)-2-nitroimidazole 
• 56271-35-3 2,3,5-tri-O-benzoyl-α,β-D-arabinofuranosyl bromide 
• 4348-68-9 2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl bromide 
• 28697-53-2 D-arabinopyranose 
• 56607-40-0 methyl D-arabinofuranoside 
• 7473-42-9 methyl tri-O-benzoyl-α-D-arabinofuranoside 
• 57236-69-8 (3S,4R,5R)-2-acetoxy-5-((benzoyloxy)methyl)tetrahydrofuran-3,4-diyl dibenzoate 
• 532-20-7 D-arabinofuranose 
• 83416-39-1 1-(2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl)-2-nitroimidazole 

Downstream Products

• 1352939-26-4 1-α-D-(5'-O-tert-butyldiphenyIsiIanoxyl-2',3'-di-O-trimethylacetyl-arabinofuranosyl)-2-nitroimidazole 
• 494775-34-7 1-α-D-(5'-O-toluenesulfonyI-arabinofuranosyl)-2-nitroimidazole 
• 1352939-20-8 1-α-D-(5'-O-(4-nitrobenzenesulfonyI)-2',3'-di-O-acetyl-arabinofuranosyl)-2-nitroimidazole 
• 1352939-30-0 1-α-D-(5'-O-(4-nitrobenzenesulfonyI)-2',3'-di-O-pivaloyl-arabinofuranosyl)-2-nitroimidazole 
• 1352939-32-2 1-α-D-(5'-O-(toluenesulfonyI)-2',3'-di-O-pivaloyl-arabinofuranosyl)-2-nitroimidazole 
• 1352939-52-6 C₁₄H₁₄N₄O₁₀S 
• 83416-39-1 1-(2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl)-2-nitroimidazole 
• 220793-03-3 fluoroazomycin arabinoside 
• 250693-28-8 1-(α-D-arabinofuranosyl)-2-aminoimidazole 
• 193150-92-4 1-(5-deoxy-5-iodo-α-D-arabinofuranosyl)-2-nitroimidazole 

Relevant academic research and scientific papers

A one-pot synthesis of 1-α- and 1-β-d-arabinofuranosyl-2- nitroimidazoles: Synthons to the markers of tumor hypoxia

1-α- and 1-β-D-Arabinofuranosyl-2-nitroimidazole (α-AZA and β-AZ A) are synthons for a number of potential markers of tissue hypoxia. A one pot synthesis in which 2-nitroimidazole is coupled with a mixture of α-and β-1-O-acetyl-2,3,5-tri-O-benzoyl-D-arabi

Synthesis of iodoaminoimidazole arabinoside (IAIA): A potential reductive metabolite of the spect imaging agent, iodoazomycin arabinoside (IAZA)

The stereospecific synthesis of 1-(5-deoxy-5-iodo-α-D- arabinofuranosyl)-2-aminoimidazole (iodoaminoimidazole arabinoside: IAIA, 2) is described. The reaction of the protected sugar bromide (8) and trifluoroacetamidoimidazole (10B) gave the coupled produc

The synthesis and radiolabeling of novel markers of tissue hypoxia of the iodinated azomycin nucleoside class

Seven second-generation hypoxic markers of the iodinated azomycin nucleoside class have been synthesized and tested for hypoxia marking activity with tumor cells in vitro and in vivo. β-D-lodoazomycin galactoside (IAZG) and β-D-lodoazomycin xylopyranoside (IAZXP) demonstrated superior hypoxia marking properties relative to IAZA because of their higher water solubilities, rapid plasma clearance rates from tumor-bearing mice and maximum tumor/blood (T/B) and tumor/muscle (T/M) ratios. Our studies with animal tumor models show that T/B or T/M ratios of these markers determined by scintigraphy or planar imaging can predict for the relative degree of tumor hypoxia and for tumor radioresistance.

Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions thereof

Compounds of the formula: STR1 wherein W is selected from the group consisting of STR2 Wherein Q is hydrogen or --CH2 OR1 ; Z is hydrogen or --OR1 ; n is 1 or 2; wherein R1 are the same or different radicals sel

Potential Radiosensitizing Agents. 6. 2-Nitroimidazole Nucleosides: Arabinofuranosyl and Hexopyranosyl Analogues

New 2-nitroimidazole nucleosides have been synthesized as radiosensitizers of hypoxic mammalian cells in an attempt to reduce the neurotoxicity and to increase the therapeutic efficacy of this class of agents.The trimethylsilyl derivative of 2-nitroimidaz